IN2014DN10283A - - Google Patents

Info

Publication number
IN2014DN10283A
IN2014DN10283A IN10283DEN2014A IN2014DN10283A IN 2014DN10283 A IN2014DN10283 A IN 2014DN10283A IN 10283DEN2014 A IN10283DEN2014 A IN 10283DEN2014A IN 2014DN10283 A IN2014DN10283 A IN 2014DN10283A
Authority
IN
India
Prior art keywords
substance
sebaceous glands
skin
choosing
topical
Prior art date
Application number
Inventor
Jean Hilaire Saurat
Original Assignee
Thesan Pharmaceuticals Inc
Jean Hilaire Saurat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thesan Pharmaceuticals Inc, Jean Hilaire Saurat filed Critical Thesan Pharmaceuticals Inc
Publication of IN2014DN10283A publication Critical patent/IN2014DN10283A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for sorting substances for the purpose of determining their capacity for sebosuppressive activity in topical skin treatment, comprising an in vivo test, the said in vivo test comprising the following steps: -choosing a substance from among the ligands of the AhR receptor; -choosing a mammal expressing the CYP1A1 gene; -treating via topical route part of the skin of the said mammal comprising sebaceous glands, with a com position comprising the said substance, following a dose/ response/response time protocol; -examining by immunohistochemical staining the expression of CYP1A in sebaceous glands of the said part of the skin of the said mam mal; -selecting the said substance as a function of the sequence of onset of immunohistochemical staining in several different types of cells of the said sebaceous glands. Pharmaceutical composition for topical use intended to re duce sebogenesis, characterized in that it contains 5,6 benzoflavone as active substance.
IN10283DEN2014 2012-05-15 2013-05-15 IN2014DN10283A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168121.7A EP2664919A1 (en) 2012-05-15 2012-05-15 A method for identifying the AhR receptor ligands having a therapeutic sebosuppressive activity
PCT/IB2013/053979 WO2013171696A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands

Publications (1)

Publication Number Publication Date
IN2014DN10283A true IN2014DN10283A (en) 2015-08-07

Family

ID=46801377

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10283DEN2014 IN2014DN10283A (en) 2012-05-15 2013-05-15

Country Status (19)

Country Link
US (2) US9480674B2 (en)
EP (2) EP2664919A1 (en)
JP (1) JP6254580B2 (en)
KR (1) KR20150022827A (en)
CN (1) CN104471391B (en)
AU (1) AU2013261093A1 (en)
BR (1) BR112014028307A2 (en)
CA (1) CA2873191A1 (en)
CO (1) CO7240392A2 (en)
HK (1) HK1205252A1 (en)
IL (1) IL235449A (en)
IN (1) IN2014DN10283A (en)
MX (1) MX2014013925A (en)
NZ (1) NZ702357A (en)
PH (1) PH12014502548A1 (en)
RU (1) RU2014150505A (en)
SG (1) SG11201407405VA (en)
WO (1) WO2013171696A1 (en)
ZA (1) ZA201408826B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082736A1 (en) 2008-01-23 2009-07-29 Jean Hilaire Saurat Pharmaceutical composition for local use
EP3360560A1 (en) 2012-03-17 2018-08-15 The Regents of the University of California Composition for treating acne
EP2664919A1 (en) 2012-05-15 2013-11-20 Jean Hilaire Saurat A method for identifying the AhR receptor ligands having a therapeutic sebosuppressive activity
EP3177365A4 (en) * 2014-08-06 2018-01-10 Thesan Pharmaceuticals, Inc. Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists
JP2016150916A (en) * 2015-02-17 2016-08-22 株式会社マンダム Sebum secretion inhibitor
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
KR20190017751A (en) 2016-04-21 2019-02-20 네이키드 바이옴, 인크. Compositions and methods for the treatment of skin disorders
US11596657B2 (en) 2016-10-04 2023-03-07 Institut National De La Recherche Agronomique Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3875098A1 (en) 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
WO2023064489A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614353A1 (en) * 1991-11-25 1994-09-14 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
AU3002299A (en) * 1998-03-16 1999-10-11 Procter & Gamble Company, The Methods for regulating skin appearance
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
FR2849597B1 (en) * 2003-01-08 2006-12-08 Oreal COSMETIC COMPOSITION FOR THE CARE OF OIL SKIN CONTAINING A CARBOXYLIC FATTY ACID OR ONE OF ITS DERIVATIVES
WO2006072203A1 (en) * 2005-01-05 2006-07-13 Oliver Yoa-Pu Hu Inhibitor or promoter of uridinediphosphate glucuronosyltransferase2b (ugt2b)
US20060210524A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin care composition
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
DE102005056890A1 (en) 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Method for evaluating effectiveness of aryl-hydrocarbon receptor agonist and antagonist comprises exposing a cell to the agonist and antagonist, treating exposed cell with UV-B radiation and determining induction of AhR-inducible gene
KR100798252B1 (en) * 2006-01-18 2008-01-24 주식회사 엘지생활건강 C-Kit activation inhibitor, skin whitening compound and composition for skin whitening containing the same
DE102006011747A1 (en) * 2006-03-13 2007-09-27 Symrise Gmbh & Co. Kg Dermatological or cosmetic preparation, useful to prevent and/or treat skin allergy, comprises a compound e.g. 3'-methoxy-4'-nitroflavone, which modulates the immunological function of the langerhans cell in skin, and carrier
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
WO2007128725A1 (en) 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg 6h-benzofuro[3,2-c] [1]benzopyran and [2] benzopyrano [4,3-b] [1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
EP2082736A1 (en) 2008-01-23 2009-07-29 Jean Hilaire Saurat Pharmaceutical composition for local use
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
KR20110139397A (en) * 2010-06-23 2011-12-29 건국대학교 산학협력단 5,6-benzoflavone having multidrug resistance inhibitory activity, a method for preparing the same and a pharmaceutical composition comprising the same
CN101953838A (en) * 2010-08-13 2011-01-26 李岱 Application of rutaecarpine in treating psoriasis
EP2664919A1 (en) 2012-05-15 2013-11-20 Jean Hilaire Saurat A method for identifying the AhR receptor ligands having a therapeutic sebosuppressive activity

Also Published As

Publication number Publication date
CN104471391A (en) 2015-03-25
JP2015523553A (en) 2015-08-13
US9480674B2 (en) 2016-11-01
KR20150022827A (en) 2015-03-04
SG11201407405VA (en) 2014-12-30
PH12014502548A1 (en) 2015-01-21
EP2850429A1 (en) 2015-03-25
NZ702357A (en) 2016-10-28
BR112014028307A2 (en) 2017-07-18
JP6254580B2 (en) 2017-12-27
EP2664919A1 (en) 2013-11-20
MX2014013925A (en) 2015-05-11
IL235449A (en) 2017-07-31
HK1205252A1 (en) 2015-12-11
WO2013171696A1 (en) 2013-11-21
US20170042856A1 (en) 2017-02-16
RU2014150505A (en) 2016-07-10
US20150057343A1 (en) 2015-02-26
CN104471391B (en) 2016-12-07
CA2873191A1 (en) 2013-11-21
AU2013261093A1 (en) 2014-12-18
CO7240392A2 (en) 2015-04-17
ZA201408826B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
IN2014DN10283A (en)
PH12015500276A1 (en) Treatment of immune-related and inflammatory diseases
AU2020202093A1 (en) Oligonucleotide-ligand conjugates and process for their preparation
IL260774B (en) Compositions comprising cd19xcd3 bispecific antibodies for the treatment of tumorous mass of lymph node tissue and/or extranodal lymphoma caused by diffuse large b cell lymphoma (dlbcl)
IN2014CN00675A (en)
EA201592269A1 (en) METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS
MX356107B (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases.
AR093377A1 (en) ANTI-NOTCH ANTIBODIES AND ANTIBODY-FARMACO CONJUGATES
MX2015008177A (en) Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions;.
WO2014066486A3 (en) Biomarker for use in treating anemia
SI2958913T1 (en) Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
EA201391764A1 (en) GLP-1 / GLUCAGON LONG-TERM RECEPTOR AGONISTS
MY175954A (en) Light-sensitive ion-passing molecules
MY175351A (en) Method and kit for measurement of nk cell activity
MX366369B (en) Method for a cell-based drug screening assay and the use thereof.
Lim et al. Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting
MA39096B1 (en) Antibodies specific to fcrn
JP2015523553A5 (en)
BR112014011758A2 (en) pharmaceutical composition, fusion protein, polynucleotide, vector, isolated cell, methods for producing a fusion protein, for treating or preventing a disease or condition, for diagnosing an individual's susceptibility to developing a disease or condition, for determining suitability of the individual to enter a drug classification experiment, and to identify an agent, use of a combination, and combination.
MX2013013691A (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient.
MA41987A (en) ANTI-IGF-1R ANTIBODIES AND ITS USE FOR CANCER DIAGNOSIS
MX2016001193A (en) Medicament comprising anti-phospholipase d4 antibody.
WO2013071038A3 (en) Antagonists for abnormal vasopressin v2 receptor and uses thereof
BR112013033807A2 (en) pyrroloquinolinyl-pyrrolidin-2,5-dione formulations and methods for their preparation
RU2013135071A (en) METHOD FOR DETERMINING ADHESIVITY OF BLOOD CELLS